[go: up one dir, main page]

WO2005040338A3 - Constrained alkaloid immunogens and antibodies and uses thereof - Google Patents

Constrained alkaloid immunogens and antibodies and uses thereof Download PDF

Info

Publication number
WO2005040338A3
WO2005040338A3 PCT/US2004/016040 US2004016040W WO2005040338A3 WO 2005040338 A3 WO2005040338 A3 WO 2005040338A3 US 2004016040 W US2004016040 W US 2004016040W WO 2005040338 A3 WO2005040338 A3 WO 2005040338A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunogens
antibodies
alkaloid
constrained
nicotine
Prior art date
Application number
PCT/US2004/016040
Other languages
French (fr)
Other versions
WO2005040338A2 (en
Inventor
Kim D Janda
Peter Wirsching
Original Assignee
Scripps Research Inst
Kim D Janda
Peter Wirsching
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Kim D Janda, Peter Wirsching filed Critical Scripps Research Inst
Publication of WO2005040338A2 publication Critical patent/WO2005040338A2/en
Publication of WO2005040338A3 publication Critical patent/WO2005040338A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Immunogens useful in the production of anti-nicotine antibodies are provided. Anti-nicotine antibodies that immunoreact with the immunogens and nicotine and uses of the immunogens and antibodies in treating nicotine addiction are also provided. Also provided are methods for enhancing the immunogenicity of a hapten by introducing a modification to constrain its conformation.
PCT/US2004/016040 2003-05-21 2004-05-20 Constrained alkaloid immunogens and antibodies and uses thereof WO2005040338A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47267103P 2003-05-21 2003-05-21
US60/472,671 2003-05-21

Publications (2)

Publication Number Publication Date
WO2005040338A2 WO2005040338A2 (en) 2005-05-06
WO2005040338A3 true WO2005040338A3 (en) 2005-10-27

Family

ID=34519951

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/016040 WO2005040338A2 (en) 2003-05-21 2004-05-20 Constrained alkaloid immunogens and antibodies and uses thereof

Country Status (1)

Country Link
WO (1) WO2005040338A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1803444B1 (en) 2002-12-20 2018-10-31 NicoNovum AB A method for the preparation of a nicotine-containing particulate material with a crystalline cellulose (in particular MCC)
EP2065398A1 (en) 2007-11-29 2009-06-03 Cytos Biotechnology AG Human monoclonal nicotine specific antibodies
WO2009120954A2 (en) * 2008-03-27 2009-10-01 The Scripps Research Institute Nicotine immunoconjugates
TWI578997B (en) 2010-06-04 2017-04-21 輝瑞疫苗有限責任公司 Conjugate for preventing or treating nicotine addiction
US9303013B2 (en) 2014-05-16 2016-04-05 Pfizer Inc. Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061054A1 (en) * 1998-05-29 1999-12-02 Independent Pharmaceutica Ab Nicotine immunogen
US20030165950A1 (en) * 1998-12-01 2003-09-04 Nabi, Inc. Hapten-carrier conjugates for treating and preventing nicotine addiction
US20050089524A1 (en) * 2002-03-01 2005-04-28 Sanderson Sam D. Compositions and compounds for use as molecular adjuvant for a nicotine vaccine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061054A1 (en) * 1998-05-29 1999-12-02 Independent Pharmaceutica Ab Nicotine immunogen
US20030165950A1 (en) * 1998-12-01 2003-09-04 Nabi, Inc. Hapten-carrier conjugates for treating and preventing nicotine addiction
US20050089524A1 (en) * 2002-03-01 2005-04-28 Sanderson Sam D. Compositions and compounds for use as molecular adjuvant for a nicotine vaccine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHINGEKI J. ET AL: "An immunotherapeutic program for the treatment of nicotine addiction: Hapten designs and synthesis.", J.ORG, CHEM., vol. 66, 2001, pages 4115 - 4121, XP008050298 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition

Also Published As

Publication number Publication date
WO2005040338A2 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
WO2007064478A3 (en) Method for making nicotine hapten
HK1088037A1 (en) Methods for the production of insulin in plants
EP1405858A8 (en) Process for producing sugar chain asparagine derivative
AU2003284371A8 (en) Improved ethanol production process
WO2006048427A8 (en) Method for producing chiral 8-(3-amino-piperidin-1-yl)-xanthines
HK1105161A1 (en) Concentrated coffee extract and process for producing the same
HK1158199A1 (en) Method for producing annelated piperazin-2-one derivatives
IL178233A0 (en) Process for producing 5-hydroxy-4-thiomethylpyrazole derivatives
ZA200405256B (en) Process for the production of hydrocarbons
HK1085462A1 (en) Piperidine derivative, process for producing the same, and use
EP1770212A4 (en) Article formed into sheet, method for producing the same and exothermic formed article
ZA200703874B (en) Process for producing natural immunobiotic extract and uses thereof
IL158016A0 (en) Method for preparing decorative elements
GB2387599B (en) Methods for producing antibodies
EP1767538A4 (en) Process for producing 1-oxacephalosporin-7alpha-methoxy-3-chloromethyl derivative
WO2005040338A3 (en) Constrained alkaloid immunogens and antibodies and uses thereof
ZA200501011B (en) Process for producing biodiesel and the product thereof
WO2002058635A3 (en) Nicotine immunogens and antibodies and uses thereof
MXPA03003874A (en) Process for the production of filled wire and plate strip to create bi-colour ornamental items as well as similarly made items.
ZA200705767B (en) Process for the preparation of a boron-substituted porphyrin
GB2422842B (en) Process for the production of multipurpose energy sources and multipurpose energy sources produced by said process
WO2005023758A3 (en) Process for the preparation of losartan potassium form i
ZA200501601B (en) Process for producing indolopyrrolocarbazole derivative
IL166374A0 (en) Novel process for producing imidazoÄ1,2-bÜpyridazine derivative
DE502006007984D1 (en) PROCESS FOR THE PRODUCTION OF FUNCTIONALIZED FUENFRINGHETEROCYCLES AND THEIR USE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase